Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELI LILLY & Co Director's Dealing 2017

Jan 31, 2017

29745_dirs_2017-01-31_8d701eee-e382-44e2-b25f-f6f910c3526b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LILLY ELI & CO (LLY)
CIK: 0000059478
Period of Report: 2017-01-27

Reporting Person: Conterno Enrique A (Sr. VP & Pres., Lilly Diabetes)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-01-27 Common Stock A 20211 $75.38 Acquired 133783 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-01-27 Restricted Stock Unit $ A 21326 Acquired 2018-02-01 Common Stock (21326.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4926 Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.